Topic: combination therapy

Pfizer sign

5. Pfizer/Array BioPharma

Buying oncology specialist Array BioPharma is Pfizer CEO Albert Bourla’s biggest M&A move so far. It represents another big bet by the New York drugmaker on cancer treatments since its $14.3 billion deal for Medivation.